Transcranial Photobiomodulation For The Management Of Depression: Current Perspectives

Paula Askalsky,1 Dan V Iosifescu1,2 1Department of Psychiatry, NYU Langone School of Medicine, New York, NY, USA; 2Clinical Research Division, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, USACorrespondence: Dan V IosifescuDepartment of Psychiatry, NYU School of Medicine, One Park...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Askalsky P, Iosifescu DV
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	low-level light therapy photobiomodulation near infrared radiation major depressive disorder depression Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/498f5347d9f5474c8589fc4b89d79bbb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:498f5347d9f5474c8589fc4b89d79bbb
record_format	dspace
spelling	oai:doaj.org-article:498f5347d9f5474c8589fc4b89d79bbb2021-12-02T03:19:30ZTranscranial Photobiomodulation For The Management Of Depression: Current Perspectives1178-2021https://doaj.org/article/498f5347d9f5474c8589fc4b89d79bbb2019-11-01T00:00:00Zhttps://www.dovepress.com/transcranial-photobiomodulation-for-the-management-of-depression-curre-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Paula Askalsky,1 Dan V Iosifescu1,2 1Department of Psychiatry, NYU Langone School of Medicine, New York, NY, USA; 2Clinical Research Division, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, USACorrespondence: Dan V IosifescuDepartment of Psychiatry, NYU School of Medicine, One Park Avenue, 8th Floor, New York, NY 10016, USATel +1 646-754-5156Email Dan.Iosifescu@nyumc.orgAbstract: Major depressive disorder (MDD) is a prevalent condition associated with high rates of disability, as well as suicidal ideation and behavior. Current treatments for MDD have significant limitations in efficacy and side effect burden. FDA-approved devices for MDD are burdensome (due to repeated in-office procedures) and are most suitable for severely ill subjects. There is a critical need for device-based treatments in MDD that are efficacious, well-tolerated, and easy to use. In this paper, we review a novel neuromodulation strategy, transcranial photobiomodulation (t-PBM) with near-infrared light (NIR). The scope of our review includes the known biological mechanisms of t-PBM, as well as its efficacy in animal models of depression and in patients with MDD. Theoretically, t-PBM penetrates into the cerebral cortex, stimulating the mitochondrial respiratory chain, and also significantly increases cerebral blood flow. Animal and human studies, using a variety of t-PBM settings and experimental models, suggest that t-PBM may have significant efficacy and good tolerability in MDD. In aggregate, these data support the need for large confirmatory studies for t-PBM as a novel, likely safe, and easy-to-administer antidepressant treatment.Keywords: low-level light therapy, photobiomodulation, near infrared radiation, major depressive disorder, depressionAskalsky PIosifescu DVDove Medical Pressarticlelow-level light therapyphotobiomodulationnear infrared radiationmajor depressive disorderdepressionNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 15, Pp 3255-3272 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	low-level light therapy photobiomodulation near infrared radiation major depressive disorder depression Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	low-level light therapy photobiomodulation near infrared radiation major depressive disorder depression Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Askalsky P Iosifescu DV Transcranial Photobiomodulation For The Management Of Depression: Current Perspectives
description	Paula Askalsky,1 Dan V Iosifescu1,2 1Department of Psychiatry, NYU Langone School of Medicine, New York, NY, USA; 2Clinical Research Division, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, USACorrespondence: Dan V IosifescuDepartment of Psychiatry, NYU School of Medicine, One Park Avenue, 8th Floor, New York, NY 10016, USATel +1 646-754-5156Email Dan.Iosifescu@nyumc.orgAbstract: Major depressive disorder (MDD) is a prevalent condition associated with high rates of disability, as well as suicidal ideation and behavior. Current treatments for MDD have significant limitations in efficacy and side effect burden. FDA-approved devices for MDD are burdensome (due to repeated in-office procedures) and are most suitable for severely ill subjects. There is a critical need for device-based treatments in MDD that are efficacious, well-tolerated, and easy to use. In this paper, we review a novel neuromodulation strategy, transcranial photobiomodulation (t-PBM) with near-infrared light (NIR). The scope of our review includes the known biological mechanisms of t-PBM, as well as its efficacy in animal models of depression and in patients with MDD. Theoretically, t-PBM penetrates into the cerebral cortex, stimulating the mitochondrial respiratory chain, and also significantly increases cerebral blood flow. Animal and human studies, using a variety of t-PBM settings and experimental models, suggest that t-PBM may have significant efficacy and good tolerability in MDD. In aggregate, these data support the need for large confirmatory studies for t-PBM as a novel, likely safe, and easy-to-administer antidepressant treatment.Keywords: low-level light therapy, photobiomodulation, near infrared radiation, major depressive disorder, depression
format	article
author	Askalsky P Iosifescu DV
author_facet	Askalsky P Iosifescu DV
author_sort	Askalsky P
title	Transcranial Photobiomodulation For The Management Of Depression: Current Perspectives
title_short	Transcranial Photobiomodulation For The Management Of Depression: Current Perspectives
title_full	Transcranial Photobiomodulation For The Management Of Depression: Current Perspectives
title_fullStr	Transcranial Photobiomodulation For The Management Of Depression: Current Perspectives
title_full_unstemmed	Transcranial Photobiomodulation For The Management Of Depression: Current Perspectives
title_sort	transcranial photobiomodulation for the management of depression: current perspectives
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/498f5347d9f5474c8589fc4b89d79bbb
work_keys_str_mv	AT askalskyp transcranialphotobiomodulationforthemanagementofdepressioncurrentperspectives AT iosifescudv transcranialphotobiomodulationforthemanagementofdepressioncurrentperspectives
_version_	1718401791395102720

Transcranial Photobiomodulation For The Management Of Depression: Current Perspectives

Ejemplares similares